{"id":3249,"date":"2018-10-24T05:24:03","date_gmt":"2018-10-24T09:24:03","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/"},"modified":"2026-09-24T00:09:45","modified_gmt":"2026-09-24T04:09:45","slug":"gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/24\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/","title":{"rendered":"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 30 septembre 2018"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le 24 octobre 2018, 7h30 CEST <\/strong>\u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 30 septembre 2018.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Situation nette de tr\u00e9sorerie<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La situation nette de tr\u00e9sorerie de GenSight Biologics s\u2019\u00e9tablissait \u00e0 39,2 millions d\u2019euros au 30 septembre 2018, compar\u00e9e \u00e0 41,7 millions d\u2019euros au 30 juin 2018.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nombre d\u2019actions composant le capital social<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Au 30 septembre 2018, le nombre d\u2019actions composant le capital social de GenSight Biologics \u00e9tait de<br>24 766 723 actions ordinaires.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GenSight Biologics publiera sa position nette de tr\u00e9sorerie au 31 d\u00e9cembre 2018 le 23 janvier 2019.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c0 propos de GenSight\u00a0Biologics<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (<em>Mitochondrial Targeting Sequence<\/em>, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, GS010, est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 24 octobre 2018, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 30 [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[76,80],"post-year":[],"class_list":["post-3249","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-type-corporate","news-type-finance"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 30 septembre 2018 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/24\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 30 septembre 2018 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 24 octobre 2018, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 30 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/24\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-24T09:24:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:09:45+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/24\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/24\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 30 septembre 2018\",\"datePublished\":\"2018-10-24T09:24:03+00:00\",\"dateModified\":\"2026-09-24T04:09:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/24\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\\\/\"},\"wordCount\":324,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/24\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/24\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\\\/\",\"name\":\"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 30 septembre 2018 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2018-10-24T09:24:03+00:00\",\"dateModified\":\"2026-09-24T04:09:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/24\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/24\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/24\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 30 septembre 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 30 septembre 2018 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/24\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 30 septembre 2018 - GenSight Biologics","og_description":"Paris, France, le 24 octobre 2018, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 30 [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/24\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/","og_site_name":"GenSight Biologics","article_published_time":"2018-10-24T09:24:03+00:00","article_modified_time":"2026-09-24T04:09:45+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/24\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/24\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 30 septembre 2018","datePublished":"2018-10-24T09:24:03+00:00","dateModified":"2026-09-24T04:09:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/24\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/"},"wordCount":324,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/24\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/24\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/","name":"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 30 septembre 2018 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2018-10-24T09:24:03+00:00","dateModified":"2026-09-24T04:09:45+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/24\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/24\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/24\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-30-septembre-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 30 septembre 2018"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3249"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3249\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3249"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3249"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3249"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3249"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}